Abstract Details

Title Creatine Kinase in SARS-CoV-2-Related Encephalopathy as a Prognostic Biomarker for Post-Acute Sequelae of COVID-19 (PASC)

Topic Neuromuscular and Clinical Neurophysiology (EMG)

Presentation(s) P9 - Poster Session 9 (5:30 PM-6:30 PM)

Poster/Presentation
Number 10-014

Objective

To investigate whether creatine kinase is a prognostic factor in SARS-CoV-2 related encephalopathy in development of PASC.

Background

Elevated CK levels have been demonstrated as a poor prognostic factor of outcomes in acute COVID-19 infection but its role as a marker of PASC is unclear.

Design/Methods A retrospective chart review was performed on hospitalized encephalopathic patients who developed COVID-19 infection during March-May of 2020 at an urban tertiary care center. Patients were divided into two subgroups according to elevated CK levels (E-CK) vs non-elevated CK levels (N-CK) with elevated defined as >200 u/L. Charts were analyzed for patients who had follow-up between 4 weeks and 1 year from initial visit to analyze subsequent development of new or persisting respiratory, cardiac, renal, or neurological symptoms to determine incidence of PASC.

Results

Of the 43 encephalopathic COVID-19 infection patients reviewed, 25 and 18 patients were found to be in the E-CK and N-CK groups, respectively (average serum CK level of 1485 u/L vs 87.11 u/L, p = 0.0026). Among the E-CK group, 14 patients (56%) had follow-up at least 4 weeks post admission in the outpatient setting vs 13 patients (72.22%) in the N-CK group (p > 0.05), with an average total follow up time of 477.37 days post initial admission in the E-CK group and 466.7857 days for N-CK (p > 0.05). In the follow-up E-CK group, 6 patients (42.85%) reported any one of the PASC symptoms whereas in the follow-up N-CK group, 9 patients (69.23%) reported any one of the PASC symptoms. (RR = 0.73, 95% CI [0.32-1.69], p = 0.47).

Conclusions Encephalopathic patients who had elevated CK levels on COVID-19 infection admission did not have an increased risk of developing PASC. Work is in progress to confirm these findings by expanding sample size, increasing follow up time, and stratifying for confounding factors.

Authors/Disclosures
Iqra Faiz PRESENTER	Miss Faiz has nothing to disclose.
Narjis Jaffry	No disclosure on file
	No disclosure on file
Mustafa Jaffry	Mr. Jaffry has nothing to disclose.
Ronak U. Trivedi	Mr. Trivedi has nothing to disclose.
Kranthi K. Mandava	Mr. Mandava has nothing to disclose.
Anam K. Shaikh (New Jersey Medical School)	Miss Shaikh has nothing to disclose.
Kazim Jaffry	Mr. Jaffry has nothing to disclose.
Muhammed Ors	Mr. Ors has nothing to disclose.
Pratibha Surathi, MD (Rutgers New Jersey Medical School)	Dr. Surathi has nothing to disclose.
Toluwalase O. Tofade, MBBS (Medstar)	Dr. Tofade has nothing to disclose.
Evan Huff, MD	Mr. Huff has nothing to disclose.
Sviatoslav Redko, MD	Dr. Redko has nothing to disclose.
Nizar Souayah, MD, FAAN (NJMS)	Dr. Souayah has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Takeda. Dr. Souayah has received publishing royalties from a publication relating to health care.

��ɫ��

��ɫ��